As shown in Table 1, patients with combined high ERβ + negative ERα expression had a significantly lower number of overall deaths and cancer recurrence events, smaller tumor extent, fewer tumor metastases in the regional lymph nodes and distant organs, predominantly stage I and II disease, and were less likely to receive adjuvant treatment after the operation. Here, ESR2 is linked to cancer.